3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
40
fludarabine
36
fludarabine phosphate
28
Tacrolimus
20
Whole-Body Irradiation
18
Mycophenolic Acid
18
Busulfan
18
Melphalan
16
thymoglobulin
14
Rituximab
13
Antilymphocyte Serum
12
venetoclax
11
Thiotepa
10
Nivolumab
9
Methotrexate
9
Granulocyte Colony-Stimulating Factor
9
Stem Cell Transplantation
8
Peripheral Blood Stem Cell Transplantation
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Cytarabine
7
Azacitidine
7
AP 1903 reagent
7
Filgrastim
6
Dexamethasone
6
aldesleukin
5
Mesna
5
Ipilimumab
5
Interleukin-2
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Inosine Monophosphate
×
Lymphoid
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled